Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 4Q2020 | JANUARY 2021 QUARTERLY NEWSLETTER

<< Previous

Bullboard Posts

Next >>

Comment by Yajneon Mar 16, 2021 12:57am

269 Views

Post# 32805460

RE:RE:4Q2020 | JANUARY 2021 QUARTERLY NEWSLETTER

Not exactly sure of purpose of posts in this thread, but as a TSX-V company, expect TLT FY2020 financials need to be reported near the end of April 2021 per requirements. The senior board (TSX) deadline is one month earlier for Q4 and FY financials.